Page last updated: 2024-11-02

oxymetazoline and Depression, Involutional

oxymetazoline has been researched along with Depression, Involutional in 1 studies

Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.

Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.

Research Excerpts

ExcerptRelevanceReference
"Patients with allergic rhinitis self-administered 56 mg of nasal esketamine after pretreatment with nasal oxymetazoline (0."5.69Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment. ( Badorrek, P; De Meulder, M; Hohlfeld, JM; Singh, J; Solanki, B; Zannikos, P, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zannikos, P1
Solanki, B1
De Meulder, M1
Badorrek, P1
Hohlfeld, JM1
Singh, J1

Trials

1 trial available for oxymetazoline and Depression, Involutional

ArticleYear
Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment.
    Clinical pharmacokinetics, 2023, Volume: 62, Issue:9

    Topics: Administration, Intranasal; Adrenal Cortex Hormones; Adult; Depressive Disorder, Major; Double-Blind

2023